Blood-Brain Barrier Penetrating Biologic TNF-α Inhibitor for Alzheimer's Disease

Molecular Pharmaceutics
Rudy ChangRachita K Sumbria

Abstract

Tumor necrosis factor alpha (TNF-α) driven processes are involved at multiple stages of Alzheimer's disease (AD) pathophysiology and disease progression. Biologic TNF-α inhibitors (TNFIs) are the most potent class of TNFIs but cannot be developed for AD since these macromolecules do not cross the blood-brain barrier (BBB). A BBB-penetrating TNFI was engineered by the fusion of the extracellular domain of the type II human TNF receptor (TNFR) to a chimeric monoclonal antibody (mAb) against the mouse transferrin receptor (TfR), designated as the cTfRMAb-TNFR fusion protein. The cTfRMAb domain functions as a molecular Trojan horse, binding to the mouse TfR and ferrying the biologic TNFI across the BBB via receptor-mediated transcytosis. The aim of the study was to examine the effect of this BBB-penetrating biologic TNFI in a mouse model of AD. Six-month-old APPswe, PSEN 1dE9 (APP/PS1) transgenic mice were treated with saline (n = 13), the cTfRMAb-TNFR fusion protein (n = 12), or etanercept (non-BBB-penetrating biologic TNFI; n = 11) 3 days per week intraperitoneally. After 12 weeks of treatment, recognition memory was assessed using the novel object recognition task, mice were sacrificed, and brains were assessed for amyloid beta ...Continue Reading

References

Nov 1, 1991·Journal of the Neurological Sciences·E M FrohmanS van den Noort
Jun 19, 1998·Brain Research. Molecular Brain Research·D ItoS Kohsaka
Oct 8, 1998·Experimental Gerontology·E G McGeer, P L McGeer
Jun 20, 2000·Neurobiology of Aging·H AkiyamaT Wyss-Coray
Oct 18, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·S J LeeE N Benveniste
Jan 5, 2002·Neurobiology of Aging·R T PerryR C Go
Aug 19, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Edith G McGeer, Patrick L McGeer
Aug 23, 2003·Journal of Neurology, Neurosurgery, and Psychiatry·E TarkowskiK Blennow
Sep 9, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Jessica Koenigsknecht-Talboo, Gary E Landreth
Jan 13, 2006·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Hantamalala Ralay RanaivoD Martin Watterson
Mar 7, 2006·Mechanisms of Ageing and Development·Domenico LioCalogero Caruso
Feb 23, 2007·Molecular Biology of the Cell·Amitabha MajumdarFrederick R Maxfield
Jul 26, 2008·The Journal of Clinical Investigation·Patricia DicksonEmil D Kakkis
Mar 12, 2009·CNS & Neurological Disorders Drug Targets·Donna M Wilcock, Carol A Colton
May 1, 2010·Nature Reviews. Drug Discovery·Martin Citron
Oct 5, 2010·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Qing-Hui ZhouWilliam M Pardridge
Feb 18, 2011·Bioengineered Bugs·William M Pardridge
Apr 20, 2011·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Qing-Hui ZhouWilliam M Pardridge
Jun 15, 2011·Journal of the American Geriatrics Society·Jian-Quan ShiJun Xu
Aug 13, 2011·The Journal of Pharmacology and Experimental Therapeutics·Qing-Hui ZhouWilliam M Pardridge
Jun 21, 2012·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Rachita K SumbriaWilliam M Pardridge
Jan 6, 2016·The British Journal of Psychiatry : the Journal of Mental Science·Judith R Harrison, Michael J Owen
Jun 7, 2016·Behavioural Brain Research·Dong Hyun KimByeong C Kim
Aug 30, 2016·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·UNKNOWN Alzheimer's Association
Sep 1, 2016·Journal of Neuroinflammation·Rachita K SumbriaMark J Fisher
Nov 30, 2016·Vascular Pharmacology·A ChakrabortyH E de Vries

❮ Previous
Next ❯

Citations

Oct 27, 2017·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·William M Pardridge
Jun 15, 2018·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Fernanda Rodriguez-OtorminMaría J Vicent
Jan 5, 2019·The American Journal of Tropical Medicine and Hygiene·Theodore E NashSiddhartha Mahanty
Jun 4, 2019·Expert Opinion on Investigational Drugs·William M Pardridge
Aug 24, 2019·The Anatomical Record : Advances in Integrative Anatomy and Evolutionary Biology·Shanglin GuoYugong Feng
Dec 18, 2019·Movement Disorders : Official Journal of the Movement Disorder Society·Christopher Bishop
Oct 30, 2019·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Jiahong SunRachita K Sumbria
Jun 5, 2019·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Lucas Taoro-GonzálezVicente Felipo
Jan 7, 2020·Médecine sciences : M/S·Pierre LafayeXavier Declèves
Mar 23, 2018·Journal of Alzheimer's Disease : JAD·Julia R ClarkeMychael V Lourenco
Jan 31, 2020·Frontiers in Aging Neuroscience·William M Pardridge
Nov 15, 2017·Seminars in Immunopathology·B Paul Morgan
May 13, 2018·International Journal of Molecular Sciences·Sophie SteelandRoosmarijn E Vandenbroucke
Dec 7, 2020·Brain : a Journal of Neurology·Shawn HayleyPaul R Albert
Aug 4, 2019·Progress in Neurobiology·Kasper Bendix JohnsenTorben Moos
Nov 20, 2020·Pharmaceuticals·William M Pardridge
Dec 31, 2020·Nutrients·Ashwinipriyadarshini MegurAurelijus Burokas
May 1, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Sarit Uzzan, Abed N Azab
May 26, 2021·Drug Development and Industrial Pharmacy·Lamia Said KandilAmira Sayed Hanafy
Jun 30, 2021·Clinical Proteomics·Angelique Florentinus-MefailoskiJohn G Marshall
Jul 2, 2020·Molecular Therapy : the Journal of the American Society of Gene Therapy·Yi LinDao Pan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Blood Brain Barrier & Cytokines

Some cytokines are able to cross the blood brain barrier through transport systems and enter the cerebrospinal fluid and interstitial fluid spaces. Here is the latest research on cytokines crossing the blood brain barrier and how this can affect tissues within the CNS.

Alzheimer's Disease: Animal Models

Alzheimer's disease is a neurodegenerative disease which can be studied using various experimental systems. This feed focuses on animal models used for Alzheimer's disease research.

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Related Papers

Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism
Rachita K SumbriaW M Pardridge
The Journal of Pharmacology and Experimental Therapeutics
Qing-Hui ZhouW M Pardridge
Drug Metabolism and Disposition : the Biological Fate of Chemicals
Qing-Hui ZhouW M Pardridge
© 2022 Meta ULC. All rights reserved